healthcare
Israeli Hospital Had Taken Patients Underground Hours Before Missile Hit
Lilly to Appeal After UK Agency Opposes Reimbursement for Alzheimer's Drug
Sixth Street-Backed Caris Life Valued at $7.7 Billion in Strong Nasdaq Debut
UK's Princess Kate, in Recovery From Cancer, to Miss Royal Ascot
Sword Health Valued at $4 Billion in General Catalyst-Led Funding Round
Date: June 17, 2025
(Reuters) -Sword Health raised $40 million in a funding round led by General Catalyst, the company said on Tuesday, valuing it at $4 billion. (Reporting by Pritam Biswas in Bengaluru; Editing by...
AstraZeneca Signs AI Research Deal With China's Cspc for Chronic Diseases
Date: June 13, 2025
(Reuters) -AstraZeneca has signed a research agreement worth more than $5 billion with Chinese drugmaker CSPC Pharmaceutical Group, the Anglo-Swedish drugmaker said on Friday. The deal marks the...
Novo Nordisk Plans to Start Late-Stage Trials of Obesity Drug Amycretin Next Year
Date: June 12, 2025
(Reuters) -Novo Nordisk said on Thursday it plans to start late-stage trials of amycretin injection and oral drugs during the first quarter of 2026 for adults who are overweight or obese. (Reporting...
German Medical Tech Firm Brainlab Plans Frankfurt IPO in Coming Weeks
Date: June 12, 2025
BERLIN (Reuters) -German medical technology firm Brainlab is planning an initial public offering on the Frankfurt Stock Exchange in the coming weeks, the company said on Thursday. The Munich-based...
Armistice Capital Is Increasing Stakes in Medical Device Companies
Date: June 12, 2025
Armistice Capital, a New York-based hedge fund known for its event-driven strategy and sector-specific convictions, is intensifying its focus on healthcare. According to its latest 13F filings with the U.S. Securities and Exchange Commission, the fund reported $7.33 billion in assets under management for the fourth quarter of 2024—marking continued growth for the firm....
Novo Signs $812 Million Weight-Loss Drug License Deal With US Biotech Deep Apple
Date: June 11, 2025
(Reuters) -Denmark's Novo Nordisk is partnering with biotech company Deep Apple Therapeutics in a deal worth up to $812 million to develop drugs for cardiometabolic diseases, including obesity, the...